DRAFT AGENDA

BLOOD PRODUCTS ADVISORY COMMITTEE 67th Meeting - September 14-15, 2000 Gaithersburg Hilton, 620 Perry Parkway Gaithersburg, MD 20877

Thursday, September 14, 2000

- 8:00 a.m. Statement of Conflict of Interest
- 8:05 a.m. Welcome and Opening Remarks
- 8:10 a.m. Committee Updates
- Summary of PHS Advisory Committee on Blood Safety and Availability Meeting, August, 24 2000 Stephen Nightingale, M.D.
- Factor VIII & vWF Standards Andrew Chang, Ph.D./Nancy Kirschbaum, Ph.D.
- Blood Supply Update Paul McCurdy, M.D

9:00 a.m. Open Committee Discussion

I. HIV p24 Antigen Testing of Plasma for Fractionation Potential Criteria for Discontinuation

- A. Introduction and Background Indira Hewlett, Ph.D., Chief, Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases
- B. Presentation Michael Busch, M.D., Ph.D., Blood Centers of the Pacific, Sacramento, CA

9:30 a.m. OPEN PUBLIC HEARING

- Presentation NGI Andrew Conrad, Ph.D.
- Presentation Alpha Therapeutics
- Presentation Aventis Charles Watson, Ph.D.
- Presentation Bayer Barbara Masecar
- Presentation Baxter
- Presentation American Red Cross Susan Stramer, Ph.D
- Presentation Abbott Laboratories Gerald Schochetman, Ph.D.
- Presentation Chiron Corporation Chyang Fang, Ph.D.

11:15 a.m. BREAK

11:45 a.m. Open Committee Discussion

- C. Question(s) for the Committee Indira Hewlett, Ph.D.
- D. Committee Discussion and Recommendations

12:45 p.m. LUNCH

- 1:45 p.m Open Committee Discussion
 - II. Deferral, As Blood or Plasma Donors, of Males Who Have Had Sex with Males
 - A. Introduction and Background Andrew Dayton, M.D., Ph.D., Medical Officer, DETTD
 - B. Epidemiology Presentation Michael Busch, M.D., Ph.D., Blood Centers of the Pacific, CA
 - C. Risk Assessment Model and Proposed Policy -Andrew Dayton, M.D., Ph.D.
- 3:15 p.m. BREAK
- 3:30 p.m. OPEN PUBLIC HEARING
- 4:00 p.m. Open Committee Discussion
 - D. Question(s) for the Committee Andrew Dayton< M.D., Ph.D.
 - E. Committee Discussion and Recommendations

5:00 p.m. RECESS (until 8:00 a.m., Friday, September 15, 2000)

Friday, September 15, 2000

8:00 a.m. Committee Updates

- Summary of Workshop on Recruiting Blood Donors Successful Practices, July 6-7, 2000 - Gilliam Conley
- Summary of Workshop on Hemopoietic Cells From Cord Blood Ellen Lazarus, M.D.
- Summary of Public Meeting on Regulation of Bone Products Ruth Solomon, M.D.
- Summary of Joint Transmissible Spongiform Encephalopathies & Vaccines and Related Biological Products Advisory Committees Meeting - David Asher, M.D.
- Update on Rapid HIV Test Approval Requirements and Standards -

Kimber L. Poffenberger, Ph.D.

8:40 a.m. Open Committee Discussion

III. Current Utility of Screening Blood Donors for Antibodies to Syphilis

- A. FDA Framework Chiang Syin, Ph.D.
- B. Background on Clinical Syphilis Lauri Markowitz, M.D., CDC
- C. Background on Diagnostic Testing for Syphilis -Roger Y. Dodd, Ph.D., ARC
- D. Syphilis Surveillance and Bloodborne TransmissionLauri Markowitz, M.D., CDC
- E. American Red Cross NAT Donor Study Sharyn Orton, Ph.D., ARC
- F. REDS Study of Syphilis Screening as a Surrogate Test - Alan Williams, Ph.D., ARC
- G. Maricopa County STD Study Lauri Markowitz, M.D., CDC
- H. CDC Proposed Studies Drs. Hsi Liu/Stephen Morse, CDC
- 10:45 a.m. BREAK

11:00 a.m. OPEN PUBLIC HEARING

11:30 a.m. Open Committee Discussion

- H. FDA Position Martin Ruta, J.D., Ph.D.
- I. Question(s) for the Committee
- J. Committee Discussion and Recommendations
- 12:30 p.m. LUNCH

1:30 p.m. IV. Classification of HLA Devices

- A. FDA Presentation of the Issue Sheryl Kochman, Chief, Devices Review Branch, Division of Blood Applications
- B. Third Party Review Program Eric Rechen, ODE, CDRH
- 1:45 p.m. OPEN PUBLIC HEARING

Industry Presentations

2:15 p.m. Open Committee Discussion

- C. Charge to the Committee Executive Secretary, BPAC
- D. Question(s) for the Committee Sheryl Kochman
- E. Committee Discussion and Recommendations

2:45 p.m. Open Committee Discussion

- V. Report of Intramural Site Visit: Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases
 - A. Introduction and Overview
 - 1. Neil Goldman, Ph.D., Associate Director for Research, CBER
 - 2. John Finlayson, Ph.D., Associate Director for Science, OBRR
 - 3. Hira Nakhasi, Ph.D., Director, Division of Emerging and Transfusion Transmitted Diseases
 - Indira Hewlett, Ph.D., Chief, Laboratory of Molecular Virology, DETTD
 - 5. Subhash Dhawan, Ph.D., Laboratory of Molecular Virology, DETTD

3:30 p.m. CLOSED COMMITTEE DISCUSSION

- B. Committee Discussion and Recommendations
- 4:00 p.m. ADJOURNMENT